Management of Type 2 Diabetes at Vihiga County referral hospital, Kenya: compliance with guidelines and prevalence of complications by Kaitany, Benjamin K et al.
Kaitany et al, Afr. J. Pharmacol. Ther. 2017. 6(1): 43-47 
 
A KeSoBAP Publication ©2017. All rights reserved. 
43 
 
Management of Type 2 Diabetes at Vihiga 
County referral hospital, Kenya: compliance 
with guidelines and prevalence of complications  
Benjamin K. Kaitany a,*, Mercy N. Mulaku a, Beatrice K. Amugune b, and 
Eric M. Guantai a  
a Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Kenya  
b Department of Pharmaceutical Chemistry, School of Pharmacy, University of Nairobi, Kenya 
_____________ 
 
* Corresponding author: Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of 
Nairobi, P.O. Box 19676-00202 , Nairobi, Kenya; Tel: +254-71-0339864; Email: bkaitany@gmail.com  
 
Background: In 2013, 382 million people suffered from diabetes globally, with 19.8 million in Africa and a Kenyan 
prevalence of 4.2%. Poor diabetic related outcomes such as complications, high blood sugar levels have resulted due 
to inadequate management of the condition. To ensure effective diagnosis, management and monitoring of Type 2 
diabetic patients, the healthcare team should adopt and adhere to standard treatment guidelines that are valid and 
up-to date  
Objective: To assess the management, monitoring and complications of Type 2 diabetes among adult outpatients at 
Vihiga County Referral Hospital, Kenya. 
Methodology: A retrospective cross sectional study design was used to obtain data from 212 patient files selected 
through a systematic random sampling. Using a pre-designed data collection form, data on patient demographics, 
blood pressure, blood sugar, weight and complications was collected. Descriptive statistics were used to summarize 
findings to determine the proportion of adult Type 2 diabetic cases diagnosed, managed and monitored as per the 
Institute of Clinical Systems Improvement (ICSI) guidelines. Inferential analysis using t-test and chi square test were 
also carried out to ascertain extent of adherence to the guidelines. 
Results: Majority of the participants (31.1%) were aged 50 – 59 years (31.1%), and most were female (70.3%). Most, 
39.6% had had diabetes for 1 to 5 years. Random blood sugar test was the most used method of diagnosis (58.5%) 
whilst fasting blood glucose test was performed in 34%. A compliance rate of 72.2% was reported in ensuring 
metformin was part of first line therapy as recommended. The recommended blood pressure, weight and cholesterol 
monitoring at initiation of treatment was observed in 96.7, 1.4 and 6.1% of the patients, respectively. Of the 141 
patients monitored using fasting blood sugar, 113 (80.1%) had uncontrolled blood sugar levels (median blood sugar = 
8.9(IQR.7.4, 12.75) mmol/L; P=0.741). The prevalence of reported neuropathy, retinopathy and nephropathy were 41, 
33 and 0.9% respectively.  
Discussion: The diagnosis, management and monitoring of most patients fell short of the ICSI treatment guideline 
recommendations especially to monitoring of blood sugar, lipid levels and weight. The presence of anomalies calls for 
sensitization of healthcare workers on the importance of adoption and adherence to evidence based, up to date 
treatment guidelines and optimize patient health outcomes. 
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In 2013, almost 382 million people suffered from 
diabetes indicating globally a prevalence of 8.3%. An 
approximate 19.8 million adults in the Africa had 
diabetes, an equivalent prevalence of 4.9% (Aguiree et 
al, 2013). The epidemiology of diabetes in Kenya has 
not been studied to any great extent but an opportunity 
sample of an urban and rural population reported a 
non-age adjusted prevalence of 4.2% in 2013 (Ayah et 
al, 2013). 
Diabetics should receive medical attention from a joint, 
integrated team of health practitioners with proficiency 
in diabetes. Treatment goals and plans should be 
identified and all patient factors, desires and wellbeing 
taken into consideration (American Diabetes 
Association, 2015). In management of Diabetes Mellitus, 
it is important that health practitioners use evidence-
based, clear, valid treatment guidelines (Woolf et al, 
1999). 
The Institute for Clinical Systems Improvement (ICSI) 
Healthcare guideline for Diagnosis and Management of 
Type 2 Diabetes Mellitus (Redmon et al, 2014), 
supplemented by The Kenya National Clinical 
Guidelines for Management of Diabetes Mellitus (2009), 
were used in this study to benchmark the diagnosis, 
management and monitoring of Type 2 Diabetes 
patients in the study area. 
As per  the ICSI recommendations, diagnosis of type 2 
diabetes should be through the use of either an A1c 
(glycated haemoglobin) test with a threshold ≥ 6.5%, 
Fasting blood Glucose(FBG) ≥ 126 mg/dL or a two-hour 
plasma glucose ≥ 200 mg/dL on a 75g Oral Glucose 
Tolerance Test(OGTT) (Redmon et al, 2014). The 
Kenyan Guidelines recommend that a patient with 
symptoms of hyperglycemia and casual plasma glucose 
or random blood sugar (RBS) ≥200 mg/dL (≥ 11.1 
mmol/L) should be diagnosed as diabetic. 
For management and monitoring, a clinician should 
personalize goals with patients to achieve glycemic 
control depending on individual patient factors. 
Allowing for normal variation in test accuracy, HbA1c 
results which range between 6.5 and 7.5% or 4.0–6.7 
mmol/L fasting blood glucose and 8–10 mmol/L 
postprandial blood glucose would reflect this goal 
(Redmon et al, 2014). When hypertension is identified, 
it should be aggressively treated to achieve target blood 
pressure levels of less than 140/90 mmHg (Redmon et 
al, 2014).  
Diabetes complications occur as result of the injurious 
effects of hyperglycemia, and include macrovascular 
complications (coronary artery disease, peripheral 
arterial disease, and stroke) and microvascular 
complications (diabetic nephropathy, neuropathy, and 
retinopathy) (Fowler, 2008). Studies elsewhere report 
varied prevalences of these diabetic complications 
(Litwak et al, 2013).  
The incidence of diabetes is increasing in Kenya (Ayah 
et al, 2013), and poor diabetic related outcomes have 
perhaps contributed to inappropriate management of 
the condition. There are few studies on compliance to 
Type 2 diabetes treatment guidelines in our setting 
therefore this study intended to address this knowledge 
gap. The main objective of this study was therefore to 
assess the management, monitoring and complications 
of Type 2 diabetes among adult outpatients at Vihiga 
County Referral Hospital, Kenya. 
2. Methods 
2.1 Study site  
The study site was Vihiga County Referral Hospital, the 
largest public hospital in Vihiga County that has a bed 
capacity of 160 beds. The hospital is situated in a rural 
set up and no such study has been previously carried 
out in a rural set up in Kenya. According to Kenya 
County Data Sheets 2014, the county has an adult 
population of approximately 246,000 persons. 
2.2 Study design and population 
A retrospective cross sectional study design was used, 
whereby the 212 patient files for adult patients aged 
≥18years with Type 2 diabetes as the primary diagnosis 
and who attended routine medical outpatient clinic 
between January and June 2015 were included in the 
study.  
2.3 Data collection  
The sampled files were retrieved and data on the 
variables and outcomes of interest extracted. The data 
collected was entered into a predesigned data collection 
form. The primary outcome of interest was the cases 
diagnosed and managed in accordance with ICSI 
treatment guidelines. The independent variables 
included age, gender, duration of disease, methods of 
diagnosis, prescribed diabetes drug therapy and 
diabetes associated complications. Achievement of the 
standard treatment targets was determined during 
analysis. 
2.4 Data analysis 
The collected data was entered to IBMR SPSSR Statistics 
version 22 and summarised using descriptive statistics 
to determine the proportion of adult Type 2 diabetic 
cases diagnosed, managed and monitored as per the 
Institute of Clinical Systems Improvement (ICSI) 
guidelines. Inferential analysis using t-test and chi 
square test were then carried out to ascertain extent of 
adherence to the ICSI guidelines. 
2.5 Ethical considerations 
Ethical approval was sought and obtained from the 
Kenyatta National Hospital-University of Nairobi Ethics 
and Research Committee (Ref: P641/10/2015) 
Patient records were anonymised and any patient 
identifiers removed to assure confidentiality of patient 
information.  
3. Results  
From the 212 patient files that were retrieved majority 
of the participants were between ages 50 and 79 years 
Kaitany et al, Afr. J. Pharmacol. Ther. 2017. 6(1): 43-47 
 
A KeSoBAP Publication ©2017. All rights reserved. 
45 
with females being most affected (70.3) as shown in 
Table 1. Most reported duration of illness was for less 
than 5 years. 
 
Table 1: Distribution of patients as per the Age and 
duration of illness (n=212) 
Demographics n % 
Age( years)   
20 - 29  4 1.9 
30 - 39  7 3.3 
40 - 49  23 10.8 
50 - 59  66 31.1 
60 - 69  63 29.7 
70 - 79  41 19.3 
≥80 years  8 3.8 
Duration of Illness(years)  
≤5  84 39.6 
6 - 10  16 7.5 
11 - 15  12 5.7 
16 - 20  1 .5 
≥21  2 .9 
Not indicated 97 45.8 
 
A greater majority had their illness diagnosed by a 
medical officer (48.1%) while medical officers on 
internship diagnosed 22.2% of the patients. Only 1 of 
the respondents had their condition diagnosed by a 
Registered Clinical Officer.  
Measurements of RBS was the most used method of 
diagnosis with 58.5% of the patients having been 
diagnosed using this method while FBG test was used in 
34% of the respondents. Only 1% of the patients were 
diagnosed using HbA1c tests while 6.5% patients lacked 
details on method of diagnosis. 
Newly diagnosed diabetic patients initiated on 
Metformin either on monotherapy or dual therapy 
constituted 15% and 56% respectively as shown in 
Figure 1. 
Based on the patient records, almost all the patients 
(96.7%) had their blood pressure checked at initiation 
of treatment while only 6.1% of the patients had 
cholesterol levels checked and even fewer (1.4%) had 
weight measurements taken. 
The ICSI treatment guidelines recommend that patients 
on follow up have blood sugar levels monitored using 
Hb1Ac or FBG (Redmon et al, 2014). The HbA1c level 
should be maintained at <7% whereas FBG should be 
maintained in 4.4-7.0 mmol/L range. The use of RBS is 
not explicitly recommended for monitoring of blood 
sugar levels. A majority of the patients (66.5%) had 
their blood sugar monitored using the FBG test 
compared to RBS test (31.6%); none were monitored 
using Hb1Ac. Some 1.9% of patients’ records had no 
details on blood sugar monitoring.  
Of the patients who had their blood sugar monitored 
using the FBG, 80% did not have their blood sugars 
controlled adequately as per the guidelines. The 
guidelines indicate that the blood sugars should be 
maintained below 7mmol/L. The median blood sugar 
for the participants tested with FBG was compared 
against the threshold value (7 mmol/L) to find out if 
they were significantly higher than this recommended 
threshold. The independent sample Mann Whitney 
result showed the median blood sugar was not 
significantly higher than the target threshold of 
7mmol/L (p=741). 
Blood pressure monitoring on follow-up was available 
for all patients with an overall mean systolic blood 
pressure of 139.56±20.94mmHg and mean diastolic 
blood pressure of 79.81±11.03mmHg during this follow 
up period.  
Amongst the patients, 188 (97.2%) had hypertension as 
comorbidity at initiation of antidiabetic treatment, and 
were therefore also put on antihypertensive treatment. 
About 52.3% of known hypertensive patients had 
maintenance blood pressures exceeding the 
recommended threshold. The ICSI guidelines 
recommend that hypertensive patients with type 2 
diabetes should be initiated on antihypertensive 
treatment and treat to a goal of < 140/90 mmHg.  
The compliance status profile for blood pressures levels 
for both systolic and diastolic is shown in Table 2. 
       Figure 1. Drugs administered at initiation 
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    Table 2: Compliance status for blood pressure control (n=212) 
Compliance status  n % 
Compliant 
  
Systolic ≤ 140mmHg  96 51.1 
Diastolic ≤ 90mmHg 162 86.2 
Non-compliant   
Systolic > 140mmHg, compliant diastolic 73 38.8 
Diastolic > 90 mmHg, compliant systolic 8 4.3 
Systolic > 140mmHg and Diastolic > 90 mmHg 19 10.1 
 
The mean systolic blood pressure of 156.54± 13.05 
mmHg in hypertensive patients with their maintenance 
systolic pressure above 140mmHg (48.9%) was found 
to be significantly higher than the target maximum 
value of 140mmHg (p<0.001).  
Similarly, the mean diastolic blood pressure of 
95.77±4.1 mmHg (13.8%), was found to be significantly 
higher than the target maximum value of 90mmHg 
(p<0.001).  
Upon follow up, only 6 (2.8%) of the patients had their 
cholesterol levels checked and recorded. None of the 
patients had their weight nor BMI recorded. 
The most common complication experienced by the 
patients was neuropathy (41%) followed by 
retinopathy (33%). The least recorded complication 
was nephropathy in only 0.9% of the patients which 
could be due to under-reporting as there were no 
records on requests for renal function tests. 
4.0 Discussion 
This study reports that patients were diagnosed 
according to the recommendation of the ISCI treatment 
guidelines with regards to the diagnostic methods used 
in testing for blood glucose levels which was a positive 
impact on practise by clinicians. The most commonly 
used methods of diagnosis were RBS and FBG compared 
to HbA1c. This is despite the fact that HbA1c is most 
prefered test as it measures chronic glucose exposure 
over a two- to three-month period and is less influenced 
by internal factors including stress and/or illness 
compared to FPG, OGTT or RBS (Redmon et al, 2014). 
None-use of HbA1c can be attributed to unavailability of 
technical resources (laboratory testing materials and 
equipment) and inadequate financial resources 
necessary to support this as a primary diagnostic 
procedure at the facility (The Kenya National Clinical 
Guidelines for Diabetes Mellitus, 2010). A study on 
laboratory medicine in Africa indicated that allocation 
of resources to diagnostic laboratory testing has not 
been a priority for resource-limited health care systems 
(Petti et al, 2006).  
When an individual’s glycaemic targets are not met by 
the combination of dietary modifications and physical 
activity, it is then recommended that oral 
pharmacotherapy be indicated with metformin as part 
of the initiation treatment (The Kenya National Clinical 
Guidelines for Diabetes Mellitus, 2010). This study 
reports a compliance of 72% to the ICSI guidelines with 
regards to first line therapy use of metformin, though 
there is much room for improvement. This finding is 
comparable to another study that reported a non-
adherence rate of 39.7% (Farsaei et al, 2010). 
In this study, almost all the patients had their blood 
pressure levels checked at diagnosis of their type 2 
diabetes, and almost all of them (89%) were 
hypertensive. These findings are consistent with other 
studies that report diabetes and hypertension 
comorbidity in approximately 40 to 60% of patients 
with type 2 diabetes  and Diabetics had a 1.5 – 3 times 
increased prevalence of hypertension compared to non-
diabetics, with 50% of adults with diabetes having 
hypertension at the time of diagnosis (Palacio et al, 
2007).  
In this study, monitoring of weight and BMI was rarely 
done contrary to the recommendation by the ICSI 
treatment guidelines. Literature suggests that over 70% 
of the people with Type 2 diabetes are either 
overweight or obese (WHO Screening for Type 2 
Diabetes, 2003). Due to this inconsistency in taking 
weight measurements, it was not clear what 
proportions of patients were overweight or obese. For 
those patients with some degree of dyslipidaemia, the 
risk of coronary artery disease and other macro-
vascular disorders is 2 to 5 times higher in people with 
diabetes than in non-diabetic subjects (Colagiuri et al, 
2004). Measurement of fasting lipids including total 
cholesterol, triglycerides and High Density Lipoprotein 
and Low Density Lipoprotein should be done annually if 
lipids are normal whilst if abnormal or on treatment, 
every 3-6 months. Over the study period, it was noted 
that very few patients had their lipid profile tested. The 
data obtained was not sufficient enough to ascertain 
extent of dyslipidaemia amongst the patients. A study 
by Krauss and Siri reported that the profile of 
cholesterol levels is important in people with type 2 
diabetes as it reflects atherogenic dyslipidemia 
characterised by small LDL-C and low HDL-C (Krauss 
and Siri, 2004). 
The ICSI treatment guidelines recommend HbA1c, FBG 
and post prandial glucose tests as ideal methods of 
monitoring glycaemic control. On contrary, not all 
patients had their blood glucose levels monitored as per 
recommendation as almost 32% of the patients were 
monitored using RBS test that is only recommended for 
purposes of diagnosis. In this study, RBS might have 
been used as an alternative monitoring test rather than 
FBG because the patients had probably taken a meal 
during the fasting period of six to eight hours required 
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before performing FBG test. For the 67% of patients 
who were tested with FBG test on follow up, 80% did 
not have their blood sugar levels controlled adequately. 
The benefits of achieving near-normal glycaemic control 
lowers risk of diabetes micro-vascular complications 
(Diabetes Trial Research group. 1995). 
The prevalence of neuropathy (41%) and retinopathy 
(33%) microvascular complications are comparable to 
that of a  study done in Malawi that showed the 
prevalences of (46.4%) and (34.7%) respectively and 
nephropathy at 34.7% (Msyamboza et al, 2014). The 
prevalence of retinopathy, neuropathy, and 
nephropathy observed in this study may have either 
been due to variation in methods of clinical care 
practised in this facility or inadequate diagnostic 
criteria for verifying presence of complications.  
A major limitation of this study could be the poor 
quality of documentation of patient characteristics and 
clinical findings in kept records, which may have 
resulted in under reporting (or over-reporting) of 
treatment target indicators and presence of severe 
complications associated with diabetes. 
5.0 Conclusion  
Majority of type 2 diabetes patients do not receive the 
right care at the right time because healthcare 
providers do not follow the clinical guidelines in the 
execution of type 2 diabetes patient care. Absence of 
diabetic specific outpatient booklet that prescribes key 
patient indicators that should be captured at every 
clinic visit has resulted in enormous missing 
information that could help in monitoring the individual 
patient progress. Healthcare providers should therefore 
either be re-oriented or trained on the importance, 
adherence and use of diabetes clinical treatment 
guidelines to optimise patients’ health outcomes. 
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